SG11202100935TA - Collagen-localized immunomodulatory molecules and methods thereof - Google Patents
Collagen-localized immunomodulatory molecules and methods thereofInfo
- Publication number
- SG11202100935TA SG11202100935TA SG11202100935TA SG11202100935TA SG11202100935TA SG 11202100935T A SG11202100935T A SG 11202100935TA SG 11202100935T A SG11202100935T A SG 11202100935TA SG 11202100935T A SG11202100935T A SG 11202100935TA SG 11202100935T A SG11202100935T A SG 11202100935TA
- Authority
- SG
- Singapore
- Prior art keywords
- collagen
- localized
- methods
- immunomodulatory molecules
- immunomodulatory
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738981P | 2018-09-28 | 2018-09-28 | |
PCT/US2019/043805 WO2020068261A1 (en) | 2018-09-28 | 2019-07-26 | Collagen-localized immunomodulatory molecules and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100935TA true SG11202100935TA (en) | 2021-02-25 |
Family
ID=67551439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100935TA SG11202100935TA (en) | 2018-09-28 | 2019-07-26 | Collagen-localized immunomodulatory molecules and methods thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US20200102370A1 (de) |
EP (1) | EP3856763A1 (de) |
JP (1) | JP2022502037A (de) |
KR (1) | KR20210068478A (de) |
CN (1) | CN112771071A (de) |
AU (1) | AU2019346335A1 (de) |
BR (1) | BR112021004383A2 (de) |
CA (1) | CA3113618A1 (de) |
IL (1) | IL281568A (de) |
MX (1) | MX2021003435A (de) |
SG (1) | SG11202100935TA (de) |
WO (1) | WO2020068261A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022538974A (ja) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | 免疫調節融合タンパク質-金属水酸化物錯体およびその方法 |
CH716227B1 (it) * | 2020-04-16 | 2020-11-30 | Contrad Swiss Sa | Composizione in gel per applicazione topica per la riduzione dell'infiammazione locale. |
CN111849910B (zh) * | 2020-05-27 | 2021-06-15 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
CN112358542A (zh) * | 2020-11-03 | 2021-02-12 | 安徽环球基因科技有限公司 | 一种重组cd36蛋白在哺乳动物细胞中的生产方法 |
US20220257715A1 (en) * | 2021-02-18 | 2022-08-18 | The Board Of Trustees Of The University Of Arkansas | Release of growth factors at wound healing stages |
EP4314029A1 (de) * | 2021-03-31 | 2024-02-07 | The Regents of University of California | Bispezifische bindemittel-ligand-fusionen zum abbau von zielproteinen |
AU2022255565A1 (en) | 2021-04-08 | 2023-11-09 | Joslin Diabetes Center, Inc. | Methods of diagnosing and predicting renal decline |
IL308240A (en) * | 2021-05-05 | 2024-01-01 | Ankyra Therapeutics Inc | Conjugated polypeptides |
AU2022315305A1 (en) | 2021-07-23 | 2024-02-01 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
CN113481167B (zh) * | 2021-08-04 | 2023-06-16 | 深圳市先康达生命科学有限公司 | 一种免疫细胞外泌体及其应用 |
CN117957257A (zh) * | 2021-08-04 | 2024-04-30 | 清华大学 | 一种靶向并杀伤病原体和/或肿瘤细胞的多功能融合蛋白药物 |
WO2023060126A1 (en) * | 2021-10-06 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Engineered cytokine receptors for tunable adoptive cell therapy |
WO2023081245A2 (en) * | 2021-11-03 | 2023-05-11 | University Of Kansas | Compositions including tumor-binding gmcsf fusion proteins and methods of using the same to treat solid tumors |
US11873507B2 (en) * | 2021-11-29 | 2024-01-16 | Replicate Bioscience, Inc. | Compositions and methods for expression of IL-12 and IL-1RA |
WO2023137291A1 (en) * | 2022-01-11 | 2023-07-20 | Board Of Regents, The University Of Texas System | Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof |
WO2023212602A2 (en) * | 2022-04-27 | 2023-11-02 | Board Of Regents, The University Of Texas System | Cd30 hinge and/or transmembrane domain-based chimeric antigen receptors |
CN114940712B (zh) * | 2022-06-01 | 2023-12-26 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
CN115806629A (zh) * | 2022-08-03 | 2023-03-17 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-CTLA4结合的融合蛋白及其应用 |
CN117402235A (zh) * | 2023-10-25 | 2024-01-16 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料iv型胶原蛋白的制备方法 |
Family Cites Families (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
ATE452207T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1261376A1 (de) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antikörper gegen ctla4(cd152), sie enthaltende konjugate und ihre verwendung |
US20020177571A1 (en) * | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
MXPA03006771A (es) | 2001-01-29 | 2004-05-05 | Idec Pharma Corp | Anticuerpos modificados y metodos de uso. |
AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
BRPI0210405B8 (pt) | 2001-06-13 | 2021-05-25 | Genmab As | anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão |
EP1852317A1 (de) | 2001-07-03 | 2007-11-07 | Delphi Korea Corporation | Seitlicher Fahrzeugairbag und Faltverfahren dafür |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
ES2466716T3 (es) | 2002-11-08 | 2014-06-11 | Ablynx N.V. | Anticuerpos de un solo dominio estabilizados |
TW200423951A (en) | 2002-11-13 | 2004-11-16 | Ming-Chung Wong | Method of preparing anti-angiogenic drug from cartilage and chondrocytes and methods of use |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
JP2007503206A (ja) | 2003-08-22 | 2007-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法 |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
EP1729795B1 (de) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albuminfusionsproteine |
EP1888649A2 (de) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen-bindungsmoleküle mit modifizierten fc-regionen und veränderte bindung an fc-rezeptoren |
EP2418278A3 (de) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
DE102006031054B4 (de) | 2006-07-05 | 2010-08-05 | Hänel & Co. | Hochregal mit Lagergutanwahl |
AU2007278994B2 (en) | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
US7842472B2 (en) | 2006-11-14 | 2010-11-30 | Alere International | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
EP2111228B1 (de) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese |
US20110038836A1 (en) | 2007-04-23 | 2011-02-17 | The Board Of Regents, The University Of Texas System | Device and Method for Transfecting Cells for Therapeutic Use |
US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
US7468685B1 (en) | 2007-08-20 | 2008-12-23 | Fairchild Semiconductor Corporation | Clockless serialization using delay circuits |
BRPI0909397A2 (pt) | 2008-03-31 | 2015-12-15 | Glaxo Group Ltd | composição, uso de uma composição, formulação, dispositivo de liberação, ácido nucléico, vetor, célula hospedeira, e, métodos para produzir um polipeptídeo de fusão |
CN101335956B (zh) | 2008-08-05 | 2011-10-05 | 国民技术股份有限公司 | 借助误码率统计数据判断通信距离的系统和方法 |
EP2169837B1 (de) | 2008-09-29 | 2013-01-30 | Telefonaktiebolaget LM Ericsson (publ) | Verfahren zur Geräuschunterdrückung in einer Übertragungsvorrichtung |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
US8457578B2 (en) | 2008-12-30 | 2013-06-04 | Qualcomm Incorporated | Discrete time receiver |
US20100210511A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination VEGFR2 Therapy with Temozolomide |
US20100322909A1 (en) | 2009-06-17 | 2010-12-23 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Th1-associated micrornas and their use for tumor immunotherapy |
CN101998390B (zh) | 2009-08-27 | 2015-03-25 | 华为技术有限公司 | 保证通信安全的方法及设备 |
DK2495243T3 (en) | 2009-10-27 | 2017-03-27 | Delta-Fly Pharma Inc | NEW 5-FLUOROURACIL DERIVATE |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US20110104128A1 (en) | 2009-10-30 | 2011-05-05 | The Board Of Regents, The University Of Texas System | Device and Method for Transfecting Cells for Therapeutic Use |
EP3527585B1 (de) | 2009-11-03 | 2022-02-16 | City of Hope | Verkürzter rezeptor des epidermalen wachstumsfaktors (egfrt) zur auswahl verkürzter t-zellen |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
AU2011223782B2 (en) | 2010-03-04 | 2014-09-18 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
CA2796338C (en) | 2010-04-13 | 2020-03-24 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
US20140086828A1 (en) | 2010-05-28 | 2014-03-27 | Aaron E. Foster | Modified gold nanoparticles for therapy |
AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
CA3157027A1 (en) | 2010-07-21 | 2012-01-26 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a t-cell receptor gene |
WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
CN103025257A (zh) | 2010-07-28 | 2013-04-03 | 斯恩蒂斯有限公司 | 使用具有径向切口的生物可降解螺钉的系统或骨头固定器 |
WO2012136231A1 (en) | 2010-09-08 | 2012-10-11 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
MX2013004792A (es) | 2010-10-27 | 2013-08-27 | Baylor College Medicine | Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas. |
WO2012071420A1 (en) | 2010-11-23 | 2012-05-31 | The Trustees Of Columbia University In The City Of New York | Enzyme combinations to reduce brain tissue swelling |
LT2649086T (lt) | 2010-12-09 | 2017-11-10 | The Trustees Of The University Of Pennsylvania | Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui |
CA2821080C (en) | 2010-12-14 | 2021-02-02 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
CN102115495B (zh) * | 2010-12-24 | 2012-07-04 | 中国人民解放军第四军医大学 | 胶原靶向治疗增生性瘢痕蛋白药物的制备及应用 |
KR101796322B1 (ko) | 2011-01-07 | 2017-12-01 | 삼성전자주식회사 | 항법 알고리즘을 이용한 위치 정보 검출 장치 및 방법 |
CA2824997C (en) | 2011-01-18 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
WO2012109659A1 (en) | 2011-02-11 | 2012-08-16 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
WO2012148552A2 (en) | 2011-02-24 | 2012-11-01 | The Research Foundation Of State University Of New York | Rectifying electromagnetic nanosensors |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
RU2688185C2 (ru) | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
GB201108236D0 (en) | 2011-05-17 | 2011-06-29 | Ucl Business Plc | Method |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
CN114835823A (zh) | 2011-07-29 | 2022-08-02 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
US20140255363A1 (en) | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
WO2013044225A1 (en) | 2011-09-22 | 2013-03-28 | The Trustees Of The University Of Pennsylvania | A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens |
JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
CA2851795C (en) | 2011-10-20 | 2018-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
US9688740B2 (en) | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
EP2780364A2 (de) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteine mit verbesserter halbwertzeit und anderen eigenschaften |
US8772058B2 (en) | 2012-02-02 | 2014-07-08 | Harris Corporation | Method for making a redistributed wafer using transferrable redistribution layers |
CN104105715B (zh) | 2012-02-13 | 2016-05-11 | 电化株式会社 | 氯丁二烯橡胶组合物、使用该氯丁二烯橡胶组合物的粘合剂组合物 |
JP2015513399A (ja) | 2012-02-22 | 2015-05-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌の治療のために有用なt細胞の存続的集団を作製するための組成物および方法 |
KR20140135715A (ko) | 2012-02-22 | 2014-11-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항종양 활성 및 car 지속을 증진시키기 위한 icos 기반 car의 용도 |
EP4275699A3 (de) | 2012-02-22 | 2024-01-03 | The Trustees of the University of Pennsylvania | Verwendung der cd2-signalisierungsdomäne bei chimären antigenrezeptoren der zweiten generation |
EP2833918B1 (de) | 2012-04-05 | 2019-05-08 | Massachusetts Institute of Technology | Immunstimulationszusammensetzungen und verfahren zur verwendung davon |
MX357823B (es) | 2012-04-11 | 2018-07-25 | Us Health | Receptores del antígeno quimérico que seleccionan el antígeno para la maduración de las células b. |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
CN104395344B (zh) | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
AU2013266734B2 (en) | 2012-05-25 | 2018-11-22 | Cellectis | Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells |
US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
MX2015000426A (es) | 2012-07-13 | 2015-07-14 | Univ Pennsylvania | Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico. |
IN2014DN11156A (de) | 2012-07-13 | 2015-10-02 | Univ Pennsylvania | |
JP5822798B2 (ja) | 2012-08-08 | 2015-11-24 | 三菱電機株式会社 | 断熱箱体及びこの断熱箱体を備えた冷蔵庫 |
US20140065629A1 (en) | 2012-08-29 | 2014-03-06 | Israel Barken | Methods of treating diseases |
WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
EP2893003B1 (de) | 2012-09-04 | 2021-03-31 | Inven2 AS | Selektive und kontrollierte expansion von nk zellen |
US9356113B2 (en) | 2012-09-05 | 2016-05-31 | Institut National Des Sciences Appliquees De Lyon | Method of producing a junction field-effect transistor (JFET) |
TW201414837A (zh) | 2012-10-01 | 2014-04-16 | Univ Pennsylvania | 標定基質細胞以治療癌症之組合物和方法 |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
DK2906684T3 (da) | 2012-10-10 | 2020-09-28 | Sangamo Therapeutics Inc | T-celle-modificerende forbindelser og anvendelser deraf |
WO2014059248A1 (en) | 2012-10-12 | 2014-04-17 | Philadelphia Health & Education Corporation D/B/A/ Drexel | Mir-155 enhancement of cd8+ t cell immunity |
JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
CA2901960C (en) | 2013-02-20 | 2022-10-04 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
US9587237B2 (en) | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
US20140274801A1 (en) | 2013-03-14 | 2014-09-18 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified t cells |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
US9393268B2 (en) | 2013-03-15 | 2016-07-19 | Thomas Jefferson University | Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same |
ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
KR20210084651A (ko) | 2013-04-18 | 2021-07-07 | 틸트 바이오세러퓨틱스 오이 | 향상된 입양 세포 치료 |
ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
AU2014273490B2 (en) | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
CN105431456A (zh) | 2013-06-14 | 2016-03-23 | 休斯敦系统大学 | 用修饰的嵌合抗原受体靶向肿瘤新生血管 |
DE102013212604A1 (de) | 2013-06-28 | 2014-12-31 | Robert Bosch Gmbh | Bearbeitungswerkzeug |
EP3021853A1 (de) | 2013-07-18 | 2016-05-25 | Baylor College Of Medicine | Verfahren zur verbesserung der wirksamkeit von immunzellen |
FR3009192B1 (fr) | 2013-07-31 | 2015-09-04 | Oreal | Composition cosmetique anhydre comprenant de l'alkylcellulose, au moins un ester ramifie de dextrine et au moins un alcool gras |
NO20131147A1 (no) | 2013-08-27 | 2014-12-22 | Langaaker John Magne | Multifunksjons varmepumpe |
MX352919B (es) | 2013-08-30 | 2017-12-14 | Hubbell Inc | Teléfono y sistema buscapersonas voip en área de riesgo con wifi. |
WO2015038684A1 (en) | 2013-09-10 | 2015-03-19 | Polyera Corporation | Attachable article with signaling, split display and messaging features |
ES2845924T3 (es) | 2013-10-15 | 2021-07-28 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos |
ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
JP6263638B2 (ja) | 2014-02-05 | 2018-01-17 | エルコーゲン オサケユキチュア | セルシステムに関する組立方法及び配置 |
US9926405B2 (en) | 2014-03-17 | 2018-03-27 | Namics Corporation | Resin composition |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
SG10201912171PA (en) | 2014-04-18 | 2020-02-27 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
KR20170068539A (ko) | 2014-10-07 | 2017-06-19 | 셀렉티스 | Car―유도된 면역 세포들 활성의 조절 방법 |
EP3209690B1 (de) | 2014-10-20 | 2021-05-05 | Juno Therapeutics, Inc. | Verfahren und zusammensetzungen zur dosierung in der adoptiven zelltherapie |
US11208661B2 (en) | 2014-10-31 | 2021-12-28 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
JP6633081B2 (ja) | 2014-12-24 | 2020-01-22 | ユーシーエル ビジネス リミテッド | 細胞 |
AU2015374296B2 (en) | 2014-12-29 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
CN107428833B (zh) | 2015-01-16 | 2021-11-02 | 朱诺治疗学股份有限公司 | Ror1特异性抗体和嵌合抗原受体 |
MA41433A (fr) | 2015-01-26 | 2017-12-05 | Baylor College Medicine | Cellules immunitaires universelles pour l'immunothérapie anticancéreuse |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016149254A1 (en) | 2015-03-17 | 2016-09-22 | Chimera Bioengineering, Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
IL302341A (en) | 2015-03-27 | 2023-06-01 | Harvard College | Modified T cells and methods for their preparation and use |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
CN104894068A (zh) | 2015-05-04 | 2015-09-09 | 南京凯地生物科技有限公司 | 一种利用CRISPR/Cas9制备CAR-T细胞的方法 |
SG10201913604TA (en) | 2015-05-28 | 2020-02-27 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
KR20180042361A (ko) | 2015-08-24 | 2018-04-25 | 셀렉티스 | 통합된 통제가능한 기능들을 가진 키메라 항원 수용체들 |
SG10202110257UA (en) | 2015-09-17 | 2021-10-28 | Novartis Ag | Car t cell therapies with enhanced efficacy |
AU2017219859A1 (en) | 2016-02-16 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
CN106399375A (zh) | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
CN106480097A (zh) | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
CN106591363A (zh) | 2016-11-11 | 2017-04-26 | 广东万海细胞生物科技有限公司 | 一种通用型异体car‑t细胞制备方法及应用 |
CN106755088A (zh) | 2016-11-11 | 2017-05-31 | 广东万海细胞生物科技有限公司 | 一种自体car‑t细胞制备方法及应用 |
WO2018112394A1 (en) * | 2016-12-15 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | Tissue-based biologics for the treatment of inflammatory and autoimmune disorders |
US10913779B2 (en) * | 2017-01-25 | 2021-02-09 | Counterpoint Biomedica Llc | Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections |
AU2019232729A1 (en) * | 2018-03-05 | 2020-10-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
-
2019
- 2019-07-26 BR BR112021004383-7A patent/BR112021004383A2/pt unknown
- 2019-07-26 AU AU2019346335A patent/AU2019346335A1/en active Pending
- 2019-07-26 KR KR1020217012024A patent/KR20210068478A/ko unknown
- 2019-07-26 MX MX2021003435A patent/MX2021003435A/es unknown
- 2019-07-26 SG SG11202100935TA patent/SG11202100935TA/en unknown
- 2019-07-26 US US16/523,965 patent/US20200102370A1/en not_active Abandoned
- 2019-07-26 JP JP2021516890A patent/JP2022502037A/ja active Pending
- 2019-07-26 WO PCT/US2019/043805 patent/WO2020068261A1/en unknown
- 2019-07-26 CN CN201980063880.8A patent/CN112771071A/zh active Pending
- 2019-07-26 CA CA3113618A patent/CA3113618A1/en active Pending
- 2019-07-26 EP EP19750220.6A patent/EP3856763A1/de active Pending
-
2021
- 2021-03-16 IL IL281568A patent/IL281568A/en unknown
-
2022
- 2022-11-18 US US18/056,825 patent/US20230174623A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL281568A (en) | 2021-05-31 |
CN112771071A (zh) | 2021-05-07 |
KR20210068478A (ko) | 2021-06-09 |
CA3113618A1 (en) | 2020-04-02 |
AU2019346335A1 (en) | 2021-03-04 |
MX2021003435A (es) | 2021-06-15 |
US20230174623A1 (en) | 2023-06-08 |
JP2022502037A (ja) | 2022-01-11 |
WO2020068261A1 (en) | 2020-04-02 |
BR112021004383A2 (pt) | 2021-08-03 |
US20200102370A1 (en) | 2020-04-02 |
EP3856763A1 (de) | 2021-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281568A (en) | Collagen-local immunomodulatory molecules and their use | |
EP3499800A4 (de) | Mikrodienstkonfigurationsvorrichtung und -verfahren | |
EP3635418A4 (de) | Vorrichtungen und verfahren zur beurteilung eines stromausfalls | |
SG11202100206TA (en) | Configuration method and device | |
GB201708940D0 (en) | Photo-bioreactor device and methods | |
ZA201806597B (en) | Ilt7 binding molecules and methods of using the same | |
EP3618795A4 (de) | Stimulationsverfahren und -vorrichtung | |
EP3703321C0 (de) | Konfigurationsverfahren und -vorrichtung | |
EP3549430A4 (de) | Gefühlsverbesserungsvorrichtung und gefühlsverbesserungsverfahren | |
GB201616152D0 (en) | Well apparatus and associated methods | |
IL278832A (en) | Improved molecules that bind 41GP | |
EP3565374A4 (de) | Regionskonfigurationsverfahren und -vorrichtung | |
GB201816911D0 (en) | Apparatus and methods | |
GB201820088D0 (en) | Opitical devices and methods | |
PL3288036T3 (pl) | Urządzenie i związane z nim sposoby | |
EP3630732A4 (de) | Verfahren und moleküle | |
GB2561023B (en) | Transducer apparatus and methods | |
GB201817825D0 (en) | Sensor methods and apparatus | |
GB201818884D0 (en) | Forthing device and method thereof | |
GB201720627D0 (en) | Fluidic apparatus and methods | |
EP3490427A4 (de) | Laryngoskopvorrichtungen und verfahren | |
ZA202100464B (en) | Fencing apparatus and fencing techniques | |
GB2588346B (en) | Apparatus and methods | |
GB201717943D0 (en) | Apparatus and methods | |
GB201704872D0 (en) | Apparatus and methods |